Surgical Innovations (GB:SUN)
LSE:SUN
Want to see GB:SUN full AI Analyst Report?
SUN Stock Chart & Stats
0.45 p
0.00 p(0.00%)
At close: 4:00 PM EST
0.45 p
0.00 p(0.00%)
Day’s Range― - ―
52-Week Range0.33 p - 0.75 p
Previous CloseN/A
Volume303.78K
Average Volume (3M)179.78K
Market Cap
£4.20M
Enterprise Value4.05M
Total Cash (Recent Filing)£813.00K
Total Debt (Recent Filing)£665.00K
Price to Earnings (P/E)―
Beta0.13
Next Earnings
Sep 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding932,816,160
10 Day Avg. Volume43,249
30 Day Avg. Volume179,777
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.55
Price to Sales (P/S)0.36
P/FCF Ratio8.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageA very low debt-to-equity (~0.09 in 2025) and materially reduced total debt give the company financial resilience. This conservatism preserves flexibility to fund product development, withstand procedure-volume shocks, or support working capital without forcing dilutive financing in the near term.
Improved Cash GenerationA return to positive operating and free cash flow in 2025 indicates the business can generate cash from operations again after a weak 2024. Durable cash generation, even at modest scale, supports liquidity, funds reinvestment in R&D and manufacturing, and reduces reliance on external capital.
Recurring Consumable SalesThe company's revenue mix includes single-use consumables tied to surgical procedure volumes, creating recurring demand and predictable replacement cycles. Such per-procedure products can provide steady revenue backstop and higher lifetime customer value versus one-off instrument sales.
Bears Say
Revenue WeaknessSustained flat-to-declining top-line (2025 down ~2.6%) undermines operating leverage and constrains reinvestment capacity. Over multiple years this trend may reflect pricing pressure, competitive displacement, or weaker procedure volumes, all of which hinder durable margin expansion and scale.
Ongoing LossesThe company remains loss-making with negative operating profit and a ~-7.7% net margin in 2025. Persistent losses erode equity and limit capacity to self-fund growth initiatives, increasing dependence on external financing if cash generation weakens or strategic investments are required.
Equity Erosion & Negative ROEDeclining shareholder equity and negative returns on equity over 2023–2025 signal value erosion from continued losses. This reduces balance sheet buffer for shocks, may raise cost of capital, and reflects that operational improvements have yet to translate into sustainable shareholder returns.
Surgical Innovations News
SUN FAQ
What was Surgical Innovations’s price range in the past 12 months?
Surgical Innovations lowest share price was 0.33 p and its highest was 0.75 p in the past 12 months.
What is Surgical Innovations’s market cap?
Surgical Innovations’s market cap is £4.20M.
When is Surgical Innovations’s upcoming earnings report date?
Surgical Innovations’s upcoming earnings report date is Sep 16, 2026 which is in 141 days.
How were Surgical Innovations’s earnings last quarter?
Surgical Innovations released its earnings results on Apr 21, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Surgical Innovations overvalued?
According to Wall Street analysts Surgical Innovations’s price is currently Overvalued.
Does Surgical Innovations pay dividends?
Surgical Innovations does not currently pay dividends.
What is Surgical Innovations’s EPS estimate?
Surgical Innovations’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Surgical Innovations have?
Surgical Innovations has 932,816,160 shares outstanding.
What happened to Surgical Innovations’s price movement after its last earnings report?
Surgical Innovations reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Surgical Innovations?
Currently, no hedge funds are holding shares in GB:SUN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Surgical Innovations
Surgical Innovations Group plc, together with its subsidiaries, designs, develops, manufactures, and sells devices for use in minimally invasive surgery (SI) and precision engineering markets in the United Kingdom, Europe, the Asia Pacific, the United States, and internationally. It operates through three segments: SI Brand, Original Equipment Manufacturer (OEM), and Distribution. The company's SI Brand segment researches, develops, manufactures, and distributes SI branded minimally invasive devices. This segment also offers YelloPort Elite and YelloPort +plus laparoscopic port access systems; LogiRange resposable laparoscopic instrument systems; FastClamp laparoscopic clamping systems; and QuickRange single use laparoscopic instrumentation. Its OEM segment researches, develops, manufactures, and distributes minimally invasive devices for third party medical device companies through own label or co-branding. This segment also provides design and development solutions for producing a final device; and researches, develops, manufactures, and sells minimally invasive technology products for precision engineering applications. The company's Distribution segment distributes medical products through Elemental Healthcare Ltd. It also designs and manufactures autologous blood products. It sells its products through independent healthcare distributors, as well as its own label products through OEM relationships. Surgical Innovations Group plc was incorporated in 1988 and is based in Leeds, the United Kingdom.
Technical Analysis
Advanced Medical Solutions
―
Creo Medical
―
―
Smith & Nephew
―
TruSpine Technologies Plc
―